Accordingly, JQ1 has been demonstrated to potentiate ibrutinib activity in both in vitro and in vivo models of ABC-DLBCL, mediated by synergistic inhibition of NF-κB-driven signaling [68]. Here, NFKB1 is linked to diffuse large B-cell lymphoma.